seminar

QB3 Seminar: Wendell Lim, UCSF. "Cell Design Labs from Launch to Acquisition"

Wendell Lim, a leader in synthetic biology, chairs the Department of Cellular and Molecular Pharmacology at UCSF. He co-founded Cell Design Labs in 2015 with Brian Atwood of Versant Ventures. Cell Design Labs, developing two technologies in the CAR-T cell cancer immunotherapy space, made such rapid progress that it was acquired two years later by Gilead for $567 million. Join us to hear about Wendell's experience launching Cell Design Labs and the lessons he learned commercializing a cutting-edge technology.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, December 6

About the Speaker

Wendell_Lim_molecule.jpg

Wendell Lim is the Byers Distinguished Professor and Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco, and an Investigator of the Howard Hughes Medical Institute. He received his A.B. in Chemistry, summa cum laude, from Harvard College, his Ph.D. in Biochemistry and Biophysics at the Massachusetts Institute of Technology and completed his postdoctoral training at Yale University. His research focuses on the design principles of molecular circuits that govern cell decision-making and responses. His lab has made contributions in understanding the molecular machinery of cell signaling and how molecular modules have been used in evolution to build novel new behaviors. Most recently he has been a pioneer in the emerging field of synthetic biology, exploring how these design principles can be harnessed to engineer cells with customized therapeutic response programs. He is an author of the textbook, Cell Signaling (Garland Science 2014) and was the founder of the cell therapy biotech startup, Cell Design Labs, which was acquired by Gilead Biosciences in 2017.

Rosenman D-Series: Sanaz Saatchi, CrownPoint Medical: "Approaches to Innovation: From Strategics to Start-Ups"

How are areas of opportunity for medtech invention discovered? Is there a single optimal approach to healthcare innovation or are there multiple approaches that work equally well? Do global healthcare companies use the same framework for innovation as start-up companies? Join us on October 30th to hear Dr. Sanaz Saatchi’s perspective and recommended methodologies to drive innovation. Previously, Dr. Saatchi led the development of cardiovascular medical devices from inception to commercial launch at Medtronic and helped multiple start-up companies determine the strategic product-market fit for novel technologies.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:00 to 6:30 PM, Tuesday, October 30

Agenda

5:00 - 5:30 pm: Networking
5:30 - 6:30 pm: Talk and Q&A

About the Speaker

Sanaz Bio Pic_2018.jpg

Sanaz has a unique combination of technical leadership and marketing expertise. While at Medtronic as an R&D Engineering Manager, she led a cross-company team to develop two cardiovascular medical devices through all phases of innovation - from inception to commercial launch. This includes needs finding, concept generation, device design, product development, high volume manufacturing, and global commercial launch. Medtronic's decision to invest in the coronary therapy delivery space with the development of these two new products stemmed directly from a global needs finding initiative led by Sanaz in partnership with IDEO. She played a critical role in conducting the research, synthesizing a strategy, and gathering organizational support to create multiple new product development programs.

Beyond her technical leadership capabilities, Sanaz also has a critical understanding of the medical device industry business needs, customer interface, and commercialization process. As a Product Marketing Manager at Medtronic, Sanaz helped drive the global launch of these two cardiovascular medical devices with a $250M market size. In addition to engineering, marketing, and leadership roles in public companies, including Medtronic and Becton Dickinson, Sanaz also has experience in technical and strategic consulting to start-ups, venture capital firms, and non-profit organizations.

Sanaz has expertise in the Stanford BioDesign Process to identify unmet healthcare needs and develop solutions. Sanaz holds a Ph.D. in Bioengineering from Stanford University, a M.S. in Mechanical Engineering from MIT, and a B.S. in Bioengineering from UC Berkeley. She is an inventor and published author on 10 patents and scientific publications, and an invited speaker at various conferences, including Cardiovascular Research Technologies and MedTech Vision highlighting female leaders within the medtech industry.

Rosenman D-Series: Rajan Patel, iO life science. "Learn About Experience Design for Medical Devices"

If your product addresses a viable market, it will have competition. Your commercial success can depend to a large extent on the good or bad experience that users--clinicians and patients--have while using your device or system. How can you ensure that users have a good experience? Join us to learn from Rajan Patel, founder and CEO of the firm iO life science. (Speaker info has been updated from the original)

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Thursday, November 29, 2018, 5:30 to 6:30 PM

Agenda

5:30 - 6:15 PM: Talk
6:15 - 6:30 PM: Q&A

About the Speaker

patel+lg 300.png

Rajan Patel is a medical device executive who partners with healthcare brands to transform their design & development practices. After 30+ years of medical device development across drug delivery, diagnostic systems, surgical devices and digital medicine, Rajan knows what truly drives innovation of smart, connected and patient-centric devices. It’s about collaborating with partners who are dedicated to creating breakthrough therapeutic solutions to unmet patient needs. Rajan has held senior positions across such companies as Minimed, Heartport, Aerogen, M2 Medical, Cirtec Medical and Lunar, leading programs to develop & commercialize medical products. Rajan’s commitment over the past 15+ years has been to organizations dedicated to transforming lives through revolutionary drug delivery and medical device technologies. Rajan has led numerous research & development and manufacturing teams to successful execution and launch of life-impacting devices. Rajan holds a B.S. in Mechanical Engineering from MS University of Baroda and M.S. in Biomedical Engineering from UC Davis/CSUS.

QB3 Seminar: Amy Trejo, P&G: "Partnering, Business Models, and Consumer Insight at P&G"

The consumer products company Procter & Gamble maintains a strong initiative in innovation, developing new products to meet consumer needs. Partnership, licensing, and acquisition are all active options. P&G actively seeks startups with technologies in areas of Life Science (including microbiome and aging), Chemistry, Materials Science, Smart Products (including AI) and Advanced Packaging. Join us to hear from Amy Trejo, Open Innovation Manager at P&G, about the company’s perspective and insights on innovation in consumer products. View the P&G one-page needs statement

Interested in meeting one-on-one with Dr. Trejo before her talk to discuss partnering with P&G? Apply for a timeslot

Where & When

Tuesday, November 27, 2018
Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)

About the Speaker

AVT-headshot1.jpg

Amy Trejo received her BSc. in Biology from Smith College in Northampton, MA and PhD in Cell and Molecular Biology from Northwestern University in Chicago, IL. She started with The Procter & Gamble Company in Cincinnati, OH in 1998 with responsibility for developing up-stream skin care technology for P&G’s Olay skin care brand. From there she moved on to manage upstream technology in the Health Care category working on digestive wellness brands with focus on the Align probiotic product. She then moved into product development managing new product innovation for Head & Shoulders. For the past 4 years Amy has worked as part of the Corporate Open Innovation Team, working to bring the best of external technologies into P&G to accelerate and strengthen their R&D programs.

Meet the FDA: Kyung Sung & Johnny Lam, FDA-CBER. "Regulatory science insights into cell-based products and practical microscale technologies for their assessment"

"Regulatory science insights into cell-based products and practical microscale technologies for their assessment"

Kyung Sung, Ph.D., Principal Investigator

Johnny Lam, Ph.D., Staff Fellow

Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research

This event is held in partnership with UCSF-Stanford CERSI.

As described in the 21st Century Cures Act, products eligible for Regenerative Medicine Advanced Therapy (RMAT) designation include cellular therapies, therapeutic tissue engineered products, human cell and tissue products, or any combination products that use such therapies or products. Multipotent stromal cells (MSCs) and induced Pluripotent Stem Cells (iPSCs) have been popular sources for manufacturing RMAT products due to their ability to undergo lineage-specific differentiation. Despite great promise, successful clinical translation of such cell-based products is often hindered by manufacturing challenges and the lack of reliable markers that can predict the products’ in vivo performance. For instance, MSCs are very heterogeneous and responsive to their surrounding environment, resulting in distinct subpopulations of cells with potentially different amounts of qualities needed for product potency. Since there are numerous biochemical and biomechanical factors regulating the functions of MSCs, it is critical to develop reliable high-throughput assays that enable the efficient exploration of large and complex parameter spaces for evaluating cellular function. Microscale in vitro systems offer the practicality to fulfill this unmet need. Several simple microfluidic channel arrays have been successfully implemented in screening the influence of paracrine mediators and various tissue microenvironment components in the regulation of cellular functions. In addition, microphysiological three-dimensional organoids and tissue-like structures such as chondrogenic cell aggregates and blood vessels have been incorporated into high-throughput, cell-based screening platforms in efforts to provide functionally relevant in vivo-like conditions. This presentation will give an overview of practical microscale technologies that are simple to operate while enhancing throughput, relevance, and reliability. How such technologies could be employed in the assessment of cell-based products will be discussed.

Where & When

Room 2103, Mission Hall, UCSF Mission Bay (550 16th St., San Francisco)
2:00-3:00 PM, Friday, November 9

About the Speakers

Johnny Lam 200px.jpg

Dr. Johnny Lam is a biomedical engineer with expertise in biomaterials and in developing practical microscale in vitro tools for medical and biological applications. Dr. Lam’s main research interests involve studying multipotent stromal cells (MSCs, otherwise known as mesenchymal stem cells) and how their quality attributes relate to their functional potential using physiologically relevant, higher-throughput platforms. Dr. Lam received his Ph.D. in Bioengineering in 2015 at Rice University, where he developed and evaluated injectable multi-layered hydrogel composites for cell and controlled growth factor delivery for in vivo cartilage tissue repair. Following his graduate studies, Dr. Lam joined the Center for Biologics Evaluation and Research at the FDA as a post-doctoral researcher, where he now works as a Staff Fellow. His research now focuses on the development and adaptation of wide-ranging microphysiological platforms to evaluate various functional outcomes of MSCs toward improving the quality and potency of manufactured cell-based products.

Kyung Sung 200px.jpg

Dr. Kyung Sung is a biomedical engineer with expertise in developing functional and practical microscale in vitro tools for medical and biological applications. Dr. Sung’s main research interests lie in studying cell-materials interactions and exploring cell behavior in various tissue microenvironmental conditions. Dr. Sung received her Ph.D. in Chemical Engineering in 2007 at the University of Michigan, and worked as a post-doctoral researcher in the Department of Biomedical Engineering at the University of Wisconsin-Madison, where she also worked as a Principal Investigator before she joined the FDA in 2015. She also worked as a patent examiner in Biotechnology at the US Patent and Trademark Office. During her previous research, she used principles from tissue and microsystems engineering to develop tissue-like structures such as blood vessels and mammary ducts in microfluidic channels to develop new practical tools to conduct cancer research in vitro. The microscale in vitro systems provide unique capabilities when studying complex interactions occurring in tissue microenvironment, by providing more precise controls of biochemical and biomechanical factors than traditional platforms. She has been able to create innovative opportunities and strategies for researchers to explore biology in different ways – particularly in understanding the role of the tissue microenvironment in regulating cellular functions.

QB3 Seminar: Lindred Greer, Stanford. "How to Build a Resilient, Winning Team"

A startup’s chances of success depend critically on the people who make up the founding team. Some conflict is inevitable, but different outlooks and temperaments among founders can ultimately make a company stronger or destroy it. What should you think about when looking for co-founders? Join us to learn from Lindred Greer, associate professor of organizational behavior at the Stanford Graduate School of Business. Professor Greer’s work focuses on the impact of team composition on intragroup conflict and team performance. She has a particular interest in how early-stage startup teams are composed in terms of power, status, and leadership structures, and when and why these structures may fuel power struggles and conflicts.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Tuesday, November 6, 2018

About the Speaker

sgsb-0004_lindred_greer-rt-web.jpg

Lindred L. Greer is an Associate Professor of Organizational Behavior and she teaches the core Groups and Teams course in the MBA program. Professor Greer’s work focuses on the impact of team composition on intragroup conflict and team performance. She has a particular interest in how teams, particularly early stage start-up teams, are composed in terms of power, status, and leadership structures, and when and why particular forms of team composition may fuel power struggles and conflicts. When investigating teams, she often adopts a multi-level theoretical approach in understanding how individuals within the same team may differentially experience team structures and processes. In carrying our her research, she employs a variety of methods, including field (ranging from survey to quasi-experimental studies), laboratory, and archival research. Her research appears in academic journals such as the Academy of Management Journal, Journal of Applied Psychology, Organizational Behavior and Human Decision Processes, and Science.

Professor Greer is on the editorial boards at the Academy of Management Journal, Administrative Science Quarterly, Journal of Applied Psychology, Journal of Experimental Social Psychology, Journal of Personality and Social Psychology, and Organizational Behavior and Human Decision Processes, and served as Associate Editor of the journal Small Group Research (2011-2015).

Professor Greer joined the Stanford Graduate School of Business in 2013. She received her BS at the Wharton School of Business at the University of Pennsylvania and her PhD in Social and Organizational Psychology at Leiden University in the Netherlands.

QB3 Seminar: Atessa Chehrazi & Ilana Drummond, Jackson & Hertogs. "US Immigration Policy for Life Science Employees and Entrepreneurs"

More than half of the startups in the QB3 network were founded by entrepreneurs not born in the US. And many startups hire foreign scientists because of their specialized skills. But the procedures for applying for visas, which have never been simple, have become more complicated of late. To learn more about how executive orders, and recent bills introduced in Congress, may affect your company’s hiring or your own employment prospects—and to get a refresher on the US immigration system—join us to hear from Atessa Chehrazi and Ilana Drummond of the San Francisco immigration law firm Jackson & Hertogs.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (700 4th St., San Francisco)
Noon to 1:00 PM, Tuesday, October 9

About the Speakers

Atessa023.JPG

Atessa Chehrazi has been a partner at Jackson & Hertogs since April 2013 and an associate/senior associate since July 2000. She was previously an associate at Maggio & Kattar in Washington, D.C. from 1996 to 2000. She has held several volunteer roles within the American Immigration Lawyers Association (AILA) during her career. For AILA’s Northern California Chapter, she has served as Chair, Vice-Chair, Treasurer, U.S. Citizenship & Immigration Service (USCIS) liaison. On a national level, Atessa served on AILA’s USCIS Headquarters and Benefits, Administrative Appeals Office (AAO), and Department of Labor (DOL) liaison committee. In addition, Atessa has served on AILA’s Business Immigration Advocacy, Issues, and Due Process & Civil Liberties committees, as well as several conference committees. She has served on both a chapter level and national level as a Customs & Border Protection (CBP) liaison.

Atessa has authored articles published in AILA Handbooks and has presented at national and regional AILA conferences. Atessa has served as a board member of the Iranian American Bar Association Northern California chapter since 2009, served as President of the chapter 2014-2015, and was the chapter honoree at the Bar Association of San Francisco Minority Bar Council annual unity awards event in 2014. She is a member of the National Lawyers Guild and was the NLG Immigration Project’s honoree in 2013.

Ilana0037.jpg

Ilana J. Drummond has been the firm’s managing partner since 2004. Having focused her practice exclusively on immigration matters for her entire career, Ilana has developed an expertise in helping large and small corporations address their immigration needs. Ilana has held a number of roles within the AILA organizations over the years, including roles within AILA’s California Service Center Liaison Committee, Distance Learning Committee, L-1 Visa Taskforce, and the USCIS Benefits Liaison Committee. Ilana has been an invited speaker to several national and regional conferences. She recently authored “Hiring International Workers in Today’s Economy: New Challenges and Strategies” to Aspatore’s 2010 edition of Employing International Workers. Ilana has received accolades from several directories to legal counsel, including Martindale-Hubbell® and Chambers USA.

QB3 Seminar: Nick Shenkin, FBI. "IP Piracy in Life Science: Threat Landscape and Defensive Tactics"

For many life science startups, IP is the most crucial factor that determines whether they succeed or fail. An innovative concept and freedom to operate are essential to winning investment.

But hostile foreign and domestic actors want to steal ideas and data from scientists and entrepreneurs. They target the most vulnerable: academics and early-stage companies.

Are you one of these targets? Do you want to know what threats you face and what you can do to protect yourself? Join us on Thursday, September 13 to hear from FBI Special Agent Nicholas Shenkin, Strategic Partnership Coordinator for the FBI’s San Francisco Field Office.

This event is co-hosted with UCSF IT Security.

Where and When

Byers Auditorium, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Noon to 1:00 PM, Thursday, September 13, 2018

About the Speaker

shenkin.jpg

Nicholas Shenkin is an FBI Special Agent and Director of the Strategic Technology Taskforce of the FBI, San Francisco Field Division. Nicholas is a Counterintelligence specialist and leads a staff of Special Agents and Intelligence Analysts responsible for hardening the target of 400+ Cleared Defense Contractors, Silicon Valley, U.C. Berkeley, Stanford, Lawrence Livermore National Lab, Lawrence Berkeley National Lab, and all businesses and academic institutions in the San Francisco division. In 1996, prior to his engagement with the Bureau, Nicholas started a web hosting and online security consultancy. Nicholas sold that company in 2002 and became Director and in-house counsel focused on M&A matters and on security compliance issues surrounding HIPAA and SOX. Nicholas is a graduate of UCLA and Loyola Law School, Los Angeles, and is a member of the California Bar.